AbCellera Biologics (ABCL) News Today → The Only Energy Play You Should Be Looking At (From Wealthpin Pro) (Ad) Free ABCL Stock Alerts $3.62 -0.16 (-4.23%) (As of 06/7/2024 08:51 PM ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 31, 2024 | americanbankingnews.comAbCellera Biologics Inc. (NASDAQ:ABCL) Short Interest Down 15.2% in MayMay 28, 2024 | businesswire.comAbCellera to Present at the Goldman Sachs 45th Annual Global Healthcare Conference on June 10, 2024May 28, 2024 | marketbeat.comAbCellera Biologics (NASDAQ:ABCL) Sees Large Volume IncreaseAbCellera Biologics (NASDAQ:ABCL) Sees Strong Trading VolumeMay 26, 2024 | marketbeat.comAbCellera Biologics Inc. (NASDAQ:ABCL) Receives Consensus Rating of "Buy" from BrokeragesAbCellera Biologics Inc. (NASDAQ:ABCL - Get Free Report) has received a consensus recommendation of "Buy" from the seven research firms that are currently covering the stock, MarketBeat reports. Seven research analysts have rated the stock with a buy recommendation. The average 12 month price targMay 23, 2024 | marketbeat.comAbCellera Biologics (NASDAQ:ABCL) Stock Price Up 2.8%AbCellera Biologics (NASDAQ:ABCL) Trading Up 2.8%May 20, 2024 | marketbeat.comAbCellera Biologics (NASDAQ:ABCL) Hits New 12-Month Low at $3.58AbCellera Biologics (NASDAQ:ABCL) Sets New 12-Month Low at $3.58May 16, 2024 | markets.businessinsider.comKeyBanc Reaffirms Their Buy Rating on AbCellera Biologics (ABCL)May 16, 2024 | seekingalpha.comAbCellera: If You Build It, Will They Come? Fresh Impetus RequiredMay 15, 2024 | seekingalpha.comAbCellera: Cash Providing Shelter From Market WeaknessMay 13, 2024 | investorplace.com3 Stock Gems Hiding in the NasdaqMay 10, 2024 | marketbeat.comBloom Burton Comments on AbCellera Biologics Inc.'s FY2026 Earnings (NASDAQ:ABCL)AbCellera Biologics Inc. (NASDAQ:ABCL - Free Report) - Bloom Burton issued their FY2026 EPS estimates for AbCellera Biologics in a research note issued on Thursday, May 9th. Bloom Burton analyst D. Martin forecasts that the company will post earnings per share of ($0.67) for the year. The consensMay 10, 2024 | finance.yahoo.comEarnings Release: Here's Why Analysts Cut Their AbCellera Biologics Inc. (NASDAQ:ABCL) Price Target To US$12.71May 8, 2024 | markets.businessinsider.comAnalysts Are Bullish on These Healthcare Stocks: ICU Medical (ICUI), AbCellera Biologics (ABCL)May 8, 2024 | markets.businessinsider.comBuy Rating Affirmed for AbCellera Biologics on Strong Financials and Promising PartnershipsMay 8, 2024 | marketbeat.comAbCellera Biologics (NASDAQ:ABCL) PT Lowered to $7.00 at KeyCorpKeyCorp lowered their target price on AbCellera Biologics from $8.00 to $7.00 and set an "overweight" rating on the stock in a research note on Wednesday.May 8, 2024 | marketbeat.comAbCellera Biologics (NASDAQ:ABCL) Releases Quarterly Earnings Results, Beats Expectations By $0.02 EPSAbCellera Biologics (NASDAQ:ABCL - Get Free Report) announced its earnings results on Tuesday. The company reported ($0.14) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.16) by $0.02. AbCellera Biologics had a negative return on equity of 12.36% and a negative net margin of 384.99%. The firm had revenue of $9.95 million during the quarter, compared to analyst estimates of $10.73 million. During the same quarter in the prior year, the company earned ($0.14) EPS. The business's revenue was down 18.4% compared to the same quarter last year.May 8, 2024 | fool.comAbCellera Biologics (ABCL) Q1 2024 Earnings Call TranscriptMay 8, 2024 | finance.yahoo.comQ1 2024 Abcellera Biologics Inc Earnings CallMay 7, 2024 | investorplace.comABCL Stock Earnings: AbCellera Biologics Beats EPS, Misses Revenue for Q1 2024May 7, 2024 | finance.yahoo.comAbCellera Biologics Inc (ABCL) Q1 2024 Earnings: Misses Revenue and Net Loss EstimatesMay 7, 2024 | businesswire.comAbCellera Reports Q1 2024 Business ResultsMay 6, 2024 | markets.businessinsider.comWhat Wall Street expects from AbCellera Biologics's earningsMay 3, 2024 | marketbeat.comAbCellera Biologics (NASDAQ:ABCL) Trading Up 7%AbCellera Biologics (NASDAQ:ABCL) Trading Up 7%May 2, 2024 | finance.yahoo.comInsider Stock Buying Reaches US$1.61m On AbCellera BiologicsMay 1, 2024 | businesswire.comAbCellera, Viking Global Investors, and ArrowMark Partners Collaborate to Launch New Biotech CompaniesApril 25, 2024 | marketbeat.comAbCellera Biologics (NASDAQ:ABCL) Sets New 52-Week Low at $3.76AbCellera Biologics (NASDAQ:ABCL) Sets New 1-Year Low at $3.76April 24, 2024 | marketbeat.comAbCellera Biologics (NASDAQ:ABCL) Trading 4.3% Higher AbCellera Biologics (NASDAQ:ABCL) Shares Up 4.3%April 18, 2024 | marketbeat.comAbCellera Biologics (NASDAQ:ABCL) Hits New 12-Month Low at $3.84AbCellera Biologics (NASDAQ:ABCL) Hits New 52-Week Low at $3.84April 18, 2024 | finance.yahoo.comAbCellera Biologics Inc. (ABCL)April 10, 2024 | marketbeat.comAbCellera Biologics Inc. (NASDAQ:ABCL) Shares Sold by Baillie Gifford & Co.Baillie Gifford & Co. trimmed its holdings in shares of AbCellera Biologics Inc. (NASDAQ:ABCL - Free Report) by 8.2% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm owned 24,044,796 shares of the company's stock after selling 2,159,853 shares during thApril 9, 2024 | marketbeat.comAbCellera Biologics (NASDAQ:ABCL) Shares Up 5.1%AbCellera Biologics (NASDAQ:ABCL) Stock Price Up 5.1%April 8, 2024 | businesswire.comAbCellera Presents Data on T-Cell Engagers Against Four Tumor Targets at AACR 2024April 6, 2024 | marketbeat.comAbCellera Biologics Inc. (NASDAQ:ABCL) Receives Average Rating of "Buy" from AnalystsAbCellera Biologics Inc. (NASDAQ:ABCL - Get Free Report) has been assigned an average rating of "Buy" from the seven research firms that are covering the stock, Marketbeat.com reports. Seven research analysts have rated the stock with a buy rating. The average 1 year price objective among analystsApril 3, 2024 | businesswire.comAbCellera to Report First Quarter 2024 Financial Results on May 7, 2024April 1, 2024 | marketbeat.comAbCellera Biologics (NASDAQ:ABCL) Trading Down 3.8%AbCellera Biologics (NASDAQ:ABCL) Trading Down 3.8%March 27, 2024 | investorplace.comThe 7 Best Penny Stocks to Buy in Q2 2024March 27, 2024 | finance.yahoo.comBillionaire Investor Stan Druckenmiller and Insiders Are Piling Into These 11 StocksMarch 26, 2024 | marketbeat.comAbCellera Biologics (NASDAQ:ABCL) Stock Price Down 3.7%AbCellera Biologics (NASDAQ:ABCL) Shares Down 3.7%March 19, 2024 | businesswire.comAbCellera to Present at the Bloom Burton Healthcare Conference on April 16, 2024March 11, 2024 | msn.comAbCellera gains on antibody collaboration with BiogenMarch 11, 2024 | marketbeat.comAbCellera Biologics (NASDAQ:ABCL) Stock Price Up 4.8%AbCellera Biologics (NASDAQ:ABCL) Trading 4.8% HigherMarch 9, 2024 | marketbeat.comSchonfeld Strategic Advisors LLC Acquires 211,000 Shares of AbCellera Biologics Inc. (NASDAQ:ABCL)Schonfeld Strategic Advisors LLC boosted its position in AbCellera Biologics Inc. (NASDAQ:ABCL - Free Report) by 143.1% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 358,400 shares of the cMarch 5, 2024 | businesswire.comAbCellera Announces Four Presentations on T-Cell Engagers at AACR 2024March 5, 2024 | marketbeat.comTrexquant Investment LP Has $1.25 Million Position in AbCellera Biologics Inc. (NASDAQ:ABCL)Trexquant Investment LP lifted its position in shares of AbCellera Biologics Inc. (NASDAQ:ABCL - Free Report) by 458.5% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 272,158 shares of the company's stock after buyiMarch 3, 2024 | marketbeat.comBarclays PLC Sells 504,978 Shares of AbCellera Biologics Inc. (NASDAQ:ABCL)Barclays PLC decreased its holdings in shares of AbCellera Biologics Inc. (NASDAQ:ABCL - Free Report) by 96.0% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 20,986 shares of the company's stock after selling 504,978 sFebruary 29, 2024 | finance.yahoo.comAfter losing 38% in the past year, AbCellera Biologics Inc. (NASDAQ:ABCL) institutional owners must be relieved by the recent gainFebruary 28, 2024 | seekingalpha.comAbCellera: Victim Of Its Own SuccessFebruary 26, 2024 | marketbeat.comFederated Hermes Inc. Cuts Position in AbCellera Biologics Inc. (NASDAQ:ABCL)Federated Hermes Inc. reduced its stake in AbCellera Biologics Inc. (NASDAQ:ABCL - Free Report) by 3.5% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 3,254,353 shares of the company's stock after selling 119,702 shares duringFebruary 26, 2024 | investorplace.com3 Highly Rated Biotech Stocks to Buy for 300% GainsFebruary 23, 2024 | markets.businessinsider.comPiper Sandler Reaffirms Their Buy Rating on AbCellera Biologics (ABCL) Get AbCellera Biologics News Delivered to You Automatically Sign up to receive the latest news and ratings for ABCL and its competitors with MarketBeat's FREE daily newsletter. Email Address Hurry! Buy this stock before the Robinhood traders do! (Ad)Robinhood traders have piled $78 billion into this market... Driving tiny tech stock gains of 3,000%, 8,942%, and 12,592% in 2020. Now their next one could be here. Click here to pay just $5 for a full year of Stealth Trades ABCL Media Mentions By Week ABCL Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ABCL News Sentiment▼0.000.76▲Average Medical News Sentiment ABCL News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ABCL Articles This Week▼02▲ABCL Articles Average Week Get AbCellera Biologics News Delivered to You Automatically Sign up to receive the latest news and ratings for ABCL and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Alpine Immune Sciences News Today Nuvalent News Today Alkermes News Today Perrigo News Today Crinetics Pharmaceuticals News Today Axsome Therapeutics News Today Ultragenyx Pharmaceutical News Today HUTCHMED News Today Prestige Consumer Healthcare News Today Corcept Therapeutics News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ABCL) was last updated on 6/10/2024 by MarketBeat.com Staff From Our PartnersIt's time to ween off Chinese lithium!As the lithium rush continues, this small-cap NASDAQ-traded company may be one of the brightest and most promi...Smallcaps Daily | SponsoredTop 5 Tech Stocks to Buy for 2024The next evolution of technology is already upending industries worth $7 Trillion… It's already got the world'...Daily Market Alerts | SponsoredTop 5 AI Stocks to Buy for 2024The electric vehicle boom is accelerating – and fast.Market Moving Trends | SponsoredNo Strings Attached: Get 30 Days of Hedgeye’s Top Stock Picks for FreeOptimize your stock investing strategy with Hedgeye's Investing Ideas, where rigorous fundamental stock analys...Hedgeye | SponsoredThe Only Energy Play You Should Be Looking AtOpen AI’s Sam Altman recently helped this company raise $577 million in funding… What’s more is, It has alr...Wealthpin Pro | SponsoredYou won't believe what Citigroup just did to it's depositorsThe FEDNOW Biden Dollar ends cash in a matter of WEEKS Stumbling Biden's dollar next phases begins Oct 21st...American Alternative | SponsoredWrite this ticker symbol down…A megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...StocksToTrade | SponsoredRSVP: Charles Payne’s Cash Flow WorkshopDid you know you could "cash flow" the stocks in your portfolio? Without selling a single share of stock? ...Unstoppable Prosperity | Sponsored